15 completed, 1 unknown. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 15, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow drospirenone: new trials by email Literature Review of drospirenone trials Research Report on drospirenone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females Drospirenone - Contraception, Change in Bone Mineral Density | Phase 3 | Completed | Insud Pharma | 1542 | 2022-08-02 | 2025-10-08 |
| The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS. Lifestyle intervention, Probiotic Agent, Oral contraceptive - Polycystic Ovary Syndrome | Phase 3 | Unknown | Peking Union Medical College Hospital | 200 | 2019-02-21 | 2019-10-10 |
| LCS16 vs. COC User Satisfaction and Tolerability Study Levonorgestrel (Kyleena, BAY86-5028), Ethinyl estradiol and drospirenone (Yarina, BAY86-5131) - Contraception | Phase 3 | Completed | Bayer | 145 | 2017-03-13 | 2023-06-18 |
| E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study 15 mg E4/3 mg DRSP - Contraception | Phase 3 | Completed | Estetra | 2148 | 2016-08-30 | 2020-02-10 |
| E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study 15 mg E4/3 mg DRSP - Contraception | Phase 3 | Completed | Estetra | 1577 | 2016-06-01 | 2019-10-04 |
| Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles LF111 (drospirenone) - Contraception | Phase 3 | Completed | Laboratories Leon Farma, S.A. | 1552 | 2014-10-09 | 2019-08-06 |
| A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) ENG 120 µg + EE 15 µg intravaginal ring, DRSP 3 mg + EE 30 µg - Contraception | Phase 3 | Completed | Organon and Co | 983 | 2011-09-19 | 2024-06-20 |
| Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne drospirenone and ethinyl estradiol, Placebo tablet - Acne Vulgaris | Phase 3 | Completed | Massachusetts General Hospital | 30 | 2009-04-01 | 2013-03-05 |
| Endometrial Safety Study 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella) - Postmenopause | Phase 3 | Completed | Bayer | 662 | 2007-08-01 | 2014-12-31 |
| Efficacy and Safety Study for an Oral Contraceptive Containing Folate Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz) - Neural Tube Defects, Contraception | Phase 3 | Completed | Bayer | 385 | 2007-04-01 | 2014-04-23 |
| Low-dose Hormone Therapy for Relief of Vasomotor Symptoms 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg) - Vasomotor Symptoms, Hot Flashes | Phase 3 | Completed | Bayer | 735 | 2007-03-01 | 2015-05-06 |
| Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea DRSP 3 mg/EE 20 µg (13 cycles), DRSP 3 mg/EE 30 µg (6 cycles) - Dysmenorrhea | Phase 2 / Phase 3 | Completed | Bayer | 420 | 2007-02-01 | 2013-01-24 |
| Efficacy and Safety Oral Contraceptive Study YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) - Contraception | Phase 3 | Completed | Bayer | 1113 | 2004-03-01 | 2014-12-31 |
| Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne. YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo - Acne Vulgaris | Phase 3 | Completed | Bayer | 534 | 2003-01-01 | 2014-12-30 |
| Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo - Acne Vulgaris | Phase 3 | Completed | Bayer | 541 | 2003-01-01 | 2014-12-30 |
| Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life. Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131) - Healthy | Phase 3 | Completed | Bayer | 221 | 2002-12-01 | 2013-10-11 |
Acne Vulgaris (3) · Hot Flashes (2) · Contraception Behavior (1) · Dysmenorrhea (1) · Neural Tube Defects (1) · Polycystic Ovary Syndrome (1)
Bayer (9) · Estetra (2) · Insud Pharma (1) · Laboratories Leon Farma, S.A. (1) · Massachusetts General Hospital (1) · Organon and Co (1) · Peking Union Medical College Hospital (1)
United States (9) · Canada (2) · Russia (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Denmark (1) · Italy (1) · Japan (1) · Mexico (1)
Enrico Colli, MD (2) · Alexandra B. Kimball, MD, MPH (1) · Rong Chen, Ph. D. (1)
PMID 37023457, PMID 18827119, PMID 21277674, PMID 21288628, PMID 21721590, PMID 21903192, PMID 22067790, PMID 22228322, PMID 23531117, PMID 23534865, PMID 23963307, PMID 23963309, PMID 24105751, PMID 27093642, PMID 27339759, PMID 29370410, PMID 33008401, PMID 37523477